Press Room

Press Release / Oct 08, 2007

Hovione in New Jersey awarded VPP Star status by OSHA

Loures, Portugal, October 8, 2007 – Hovione announces that its Technology Transfer Centre (TTC) has been accepted for Star participation to the Voluntary Protection Program by the Occupational Safety & Health Administration – OSHA. The VPP Star plaque and Flag presentation ceremony will take place next 11th October in East Windsor, New Jersey at 3pm.

At present, only 44 sites in New Jersey have obtained the VPP Star designation. Just to apply, the facilities need to have a minimum of 3 years of unblemished track record. The TTC started operations in 2001 and OSHA accepted our application less than 12 months after it was first submitted. This shows the commitment to worker safety and health that has existed at the TTC since its inception.

Guy Villax, Hovione CEO said: “I am very proud of the achievement of my colleagues. This award takes our TTC to the next level, it is a status that the Team in New Jersey will have to work hard to maintain. Continuing to deserve this is central to building our company culture. Safe operations are the result of good management and dedicated people. This is what gets customers to come back for more. I think it is terrific that, just like all our other sites, the TTC in New Jersey continues the Hovione tradition of collecting awards for doing important things well - well done!”.

Working with industry and labor, the federal Occupational Safety & Health Administration created the Voluntary Protection Program (VPP) in 1980 to recognize and partner with worksites that implement exceptional systems to manage worker safety and health. The management and employees at these sites voluntarily implement comprehensive safety & health management systems - that go far beyond basic compliance with OSHA regulations.

The VPP process emphasizes holding managers accountable for worker safety & health through measurable goals, the continual identification and elimination of hazards and the active involvement of employees in their own protection. The process places significant reliance on the cooperation and trust inherent in a partnership. Sites choosing to apply for VPP recognition show their commitment to effective worker protection by inviting government regulators into their workplace. In return, OSHA removes them from programmed inspections and does not issue citations for violations that are promptly corrected.

About Hovione
Hovione is an international group specializing in the development and compliant production of active pharmaceutical ingredients (APIs), serving exclusively the pharmaceutical industry. With FDA inspected plants in Europe and the Far East and a Technology Transfer Center in New Jersey, Hovione is committed to the highest levels of service and quality. Specializing in complex chemistry, Hovione offers services related to the development and manufacture of either a new chemical entity (NCE) for an exclusive contract manufacturing partner or an existing API for an off-patent product.

Also in the Press Room

See All

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025